Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2015 19:31 ET | Source: Novartis Pharma AG

Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients

New x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on...
November 07, 2015 19:30 ET | Source: Novartis Pharma AG

New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis

A sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained...
November 04, 2015 01:00 ET | Source: Novartis Pharma AG

Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors

Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms....
October 29, 2015 02:15 ET | Source: Novartis Pharma AG

Novartis Foundation and partners launch new hypertension program in Ghana

Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control Screening and treatment is shifted to the...
October 27, 2015 02:00 ET | Source: Novartis Pharma AG

Novartis steigert die Kerngewinnmarge (kWk) im dritten Quartal kräftig, stärkt erneut die Pipeline und ist auf Kurs für die Jahresprognose

Solides Wachstum (kWk[1]) im dritten Quartal beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie der fortzuführenden Geschäftsbereiche[2]: Der Nettoumsatz beläuft sich auf USD 12,3...
October 27, 2015 02:00 ET | Source: Novartis Pharma AG

Novartis a réalisé, au troisième trimestre, une forte hausse de sa marge core (tcc) et continué de renforcer son pipeline, confirmant ainsi ses prévisions pour l'exercice

Croissance solide (tcc[1]), au T3, des ventes, du résultat opérationnel core et du BPA core des activités poursuivies[2] Chiffre d'affaires net d'USD 12,3 milliards (-6%, +6% tcc) Résultat...
October 27, 2015 02:00 ET | Source: Novartis Pharma AG

Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance

Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc) Core...
October 23, 2015 07:25 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis

Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of action...
October 21, 2015 01:15 ET | Source: Novartis Pharma AG

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma

With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating...
October 15, 2015 01:15 ET | Source: Novartis Pharma AG

Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases

Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and...